Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy: A single-center observational study

Zhao Yabo; Lu Qiang; Sun Jianyong; Shao Qiongjie; Li Guizhen

doi:10.13406/j.cnki.cyxb.003813

您当前的位置：

首页 >

文章列表页 >

Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy: A single-center observational study

Precision medicine in cancer and translational studies | 更新时间：2025-11-20

- Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy: A single-center observational study
- Journal of Chongqing Medical University Vol. 50, Issue 11, Pages: 1515-1519(2025)
- 作者机构：
  
  空军军医大学第二附属医院胸腔外科，西安 710038
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003813
  CLC： R453.9
- Received：18 November 2024，
  
  Revised：2025-02-12，
  
  Accepted：20 February 2025，
  
  Published：28 November 2025
- 稿件说明：
移动端阅览
赵雅波,卢强,孙建勇等.探索新辅助肺癌患者预防免疫药物治疗不良事件的教育需求：一项单中心观察性研究[J].重庆医科大学学报,2025,50(11):1515-1519.

Zhao Yabo,Lu Qiang,Sun Jianyong,et al.Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy: A single-center observational study[J].Journal of Chongqing Medical University,2025,50(11):1515-1519.
赵雅波,卢强,孙建勇等.探索新辅助肺癌患者预防免疫药物治疗不良事件的教育需求：一项单中心观察性研究[J].重庆医科大学学报,2025,50(11):1515-1519. DOI： 10.13406/j.cnki.cyxb.003813.

Zhao Yabo,Lu Qiang,Sun Jianyong,et al.Educational needs for prevention of adverse events due to immunotherapy in patients with lung cancer after neoadjuvant therapy: A single-center observational study[J].Journal of Chongqing Medical University,2025,50(11):1515-1519. DOI： 10.13406/j.cnki.cyxb.003813.

摘要

目的

免疫检查点抑制剂（immune checkpoint inhibitors，ICIs）可明显改善多种癌症类型的临床预后，并越来越多地被用于肺癌手术联合治疗。然而，ICIs也可引起严重的或致命的免疫相关不良事件（immune-related adverse events，irAEs），有效的患者评估、家属相关培训，对于新辅助免疫治疗中预防irAEs是至关重要的。因此，本研究旨在确定肺癌患者在接受新辅助治疗后预防irAEs的教育需求。

方法

回顾性分析了2021年3月至2023年9月178例接受新辅助治疗肺癌患者的医疗记录。我们评估了由于irAEs所致的频率、严重程度和非计划住院情况。根据初始症状、报告员、电话咨询以及症状出现和到医院的间隔时间对教育需求进行评估。

结果

在可评估的178例患者中，86例患者（48.3%）在研究期间发生了irAEs。肺炎（13例）是最常见需要住院的irAEs，其次是皮炎和肾上腺功能不全（各2例）。在接受新辅助治疗的肺癌患者中，需要住院治疗的严重irAEs的发生率较高。

结论

通过培训患者及家属相关知识，护理人员及时评估、报告新辅助治疗后症状的轻微变化，重点关注可能严重的常见irAEs，再通过早期检测常能避免发展到严重的irAEs。

Abstract

Objective

Immune checkpoint inhibitors（ICIs） can significantly improve the clinical prognosis of various types of cancer and are increasingly used in surgical combination therapy for lung cancer. However，ICIs can cause serious or fatal immune-related adverse events（irAEs），and effective patient assessment and family training are essential for the prevention of irAEs in neoadjuvant immunotherapy. Therefore，this study aims to determine the educational needs for the prevention of irAEs in patients with lung cancer after neoadjuvant therapy.

Methods

A retrospective analysis was performed for the medical records of 178 patients with lung cancer who received neoadjuvant therapy from March 2021 to September 2023，and the frequency and severity of irAEs and unplanned hospitalization due to irAEs were evaluated. Educational needs were assessed based on initial symptoms，caregivers，telephone counselling，and the interval between the appearance of symptoms and the arrival at the hospital.

Results

Among the 178 patients available for assessment，86 patients（48.3%） experienced irAEs during the study period. Pneumonia observed in 13 patients was the most common irAE requiring hospitalization，followed by dermatitis in 2 patients and adrenal insufficiency in 2 patients. There was a relatively high incidence rate of severe irAEs requiring hospitalization among the patients with lung cancer receiving neoadjuvant therapy.

Conclusion

Severe irAEs can be avoided through training of related knowledge for patients and their families，timely assessment and reporting of slight changes in symptoms after neoadjuvant therapy by caregivers，focus on commonly observe severe irAEs，and early detection.

关键词

Keywords

references

Bray F ， Laversanne M ， Sung H ， et al . Global cancer statistics 2022：GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries [J ] . CA Cancer J Clin ， 2024 ， 74 （ 3 ）： 229 - 263 .

杜文兴，沃　杨，卢通，等 . EGFR-TKIs治疗非小细胞肺癌EGFR罕见突变的研究进展 [J ] . 中国肺癌杂志， 2019 ， 22 （ 9 ）： 590 - 599 .

Du WX ， Wo Y ， Lu T ， et al . A review of EGFR-TKIs therapy of non-small cell lung cancer with uncommon EGFR mutations [J ] . Chin J Lung Cancer ， 2019 ， 22 （ 9 ）： 590 - 599 .

Hines JB ， Cameron RB ， Esposito A ， et al . Evaluation of major pathologic response and pathologic complete response as surrogate end points for survival in randomized controlled trials of neoadjuvant immune checkpoint blockade in resectable in NSCLC [J ] . J Thorac Oncol ， 2024 ， 19 （ 7 ）： 1108 - 1116 .

Sun L ， Handorf EA ， Zhou YY ， et al . Outcomes in patients treated with frontline immune checkpoint inhibition（ICI） for advanced NSCLC with KRAS mutations and STK11/KEAP1 comutations across PD-L1 levels [J ] . Lung Cancer ， 2024 ， 190 ： 107510 .

Livanou ME ， Nikolaidou V ， Skouras V ， et al . Efficacy of NSCLC rechallenge with immune checkpoint inhibitors following disease progression or relapse [J ] . Cancers ， 2024 ， 16 （ 6 ）： 1196 .

Champiat S ， Lambotte O ， Barreau E ， et al . Management of immune checkpoint blockade dysimmune toxicities：a collaborative position paper [J ] . Ann Oncol ， 2016 ， 27 （ 4 ）： 559 - 574 .

Ramos-Casals M ， Brahmer JR ， Callahan MK ， et al . Immune-related adverse events of checkpoint inhibitors [J ] . Nat Rev Dis Primers ， 2020 ， 6 （ 1 ）： 38 .

Chitnis SD ， Mortazavi A . Clinical guideline highlights for the hospitalist：management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy [J ] . J Hosp Med ， 2023 ， 18 （ 11 ）： 1013 - 1016 .

Weber JS ， Postow M ， Lao CD ， et al . Management of adverse events following treatment with anti-programmed death-1 agents [J ] . Oncologist ， 2016 ， 21 （ 10 ）： 1230 - 1240 .

Puzanov I ， Diab A ， Abdallah K ， et al . Managing toxicities associated with immune checkpoint inhibitors：consensus recommendations from the Society for Immunotherapy of Cancer（SITC） Toxicity Management Working Group [J ] . J Immunother Cancer ， 2017 ， 5 （ 1 ）： 95 .

Wang DY ， Salem JE ， Cohen JV ， et al . Fatal toxic effects associated with immune checkpoint inhibitors：a systematic review and meta-analysis [J ] . JAMA Oncol ， 2018 ， 4 （ 12 ）： 1721 - 1728 .

Seethapathy H ， Herrmann SM ， Rashidi A . Immune checkpoint inhibitor–associated AKI：debates in diagnosis，management，and rechallenge [J ] . Semin Nephrol ， 2022 ， 42 （ 6 ）： 151346 .

Sung C ， An J ， Lee S ， et al . Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer [J ] . Nat Cancer ， 2023 ， 4 （ 6 ）： 844 - 859 .

Bayer V ， Amaya B ， Baniewicz D ， et al . Cancer immunotherapy：an evidence-based overview and implications for practice [J ] . Clin J Oncol Nurs ， 2017 ， 21 （ 2 Suppl ）： S13 - S21 .

Li YC ， Pond G ， McWhirter E . Multisystem immune-related adverse events from dual-agent immunotherapy use [J ] . Curr Oncol ， 2024 ， 31 （ 1 ）： 425 - 435 .

Cortellini A ， Chiari R ， Ricciuti B ， et al . Correlations between the immune-related adverse events spectrum and efficacy of anti-PD1 immunotherapy in NSCLC patients [J ] . Clin Lung Cancer ， 2019 ， 20 （ 4 ）： 237 - 247 .

Wood LS ， Moldawer NP ， Lewis C . Immune checkpoint inhibitor therapy：key principles when educating patients [J ] . Clin J Oncol Nurs ， 2019 ， 23 （ 3 ）： 271 - 280 .

Haanen J ， Obeid M ， Spain L ， et al . Management of toxicities from immunotherapy：ESMO clinical practice guideline for diagnosis，treatment and follow-up [J ] . Ann Oncol ， 2022 ， 33 （ 12 ）： 1217 - 1238 .

Thompson JA ， Schneider BJ ， Brahmer J ， et al . NCCN guidelines insights：management of immunotherapy-related toxicities，version 1.2020 [J ] . J Natl Compr Canc Netw ， 2020 ， 18 （ 3 ）： 230 - 241 .

McGettigan S ， Rubin KM . PD-1 inhibitor therapy：consensus statement from the faculty of the melanoma nursing initiative on managing adverse events [J ] . Clin J Oncol Nurs ， 2017 ， 21 （ 4 Suppl ）： 42 - 51 .

吴　皎，杨润祥 . 免疫检查点抑制剂相关不良事件识别与管理 [J ] . 中国临床医生杂志， 2023 ， 51 （ 10 ）： 1135 - 1137 ．

Wu J ， Yang RX . Identification and management of adverse events related to inhibitors at immune checkpoints [J ] . Chin J Clin ， 2023 ， 51 （ 10 ）： 1135 - 1137 .

李晋平，翟敏峰，王　艳 . 肺癌患者免疫治疗联合化疗期间居家休养体验的研究 [J ] . 中国护理管理， 2024 ， 24 （ 1 ）： 57 - 61 .

Li JP ， Zhai MF ， Wang Y . Home recuperation experience of lung cancer patients with immunochemotherapy：a qualitative study [J ] . Chin Nurs Manag ， 2024 ， 24 （ 1 ）： 57 - 61 .

Naing A ， Hajjar J ， Gulley JL ， et al . Strategies for improving the management of immune-related adverse events [J ] . J Immunother Cancer ， 2020 ， 8 （ 2 ）： e001754 .

Cole S ， Zibelman M ， Bertino E ， et al . Managing immuno-oncology toxicity：top 10 innovative institutional solutions [J ] . Am Soc Clin Oncol Educ Book ， 2019 ， 39 ： 96 - 104 .

Ettinger DS ， Wood DE ， Aisner DL ， et al . NCCN guidelines ® insights：non-small cell lung cancer，version 2.2023 [J ] . J Natl Compr Canc Netw ， 2023 ， 21 （ 4 ）： 340 - 350 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Application of radiological indicators combined with the methylation of HOXA7 and SOX17 in plasma circulating tumor DNA in the early diagnosis of lung cancer

Quercetin inhibits the growth of lung cancer cells and promotes cell apoptosis through targeted binding to aldolase A

An experimental study of editable DNA nanoflowers inhibiting the proliferation，migration and invasion of Lewis lung carcinoma cells

Efficacy and safety of ADC combined with PD-1 inhibitors versus GC regimen in neoadjuvant therapy for bladder cancer

Related Author

Liu Baojing

Wu Man

Feng Feixue

Zhang Yuxin

Wang Zhanzheng

Yang Ruifei

Ma Yanxia

Xu Wei

Related Institution

School of Medical Technology， Shaanxi University of Chinese Medicine

Department of Laboratory Medicine， The Affiliated Hospital of Shaanxi University of Chinese Medicine

Department of Oncology，Hebei Chest Hospital

Department of Oncology，Cangzhou People's Hospital

State Key Laboratory of Ultrasound in Medicine and Engineering，College of Biomedical Engineering， Chongqing Medical University

⁰